What is the 13F Pro Quality Score for CDIO?

13F Pro ranks Cardio Diagnostics Holdings, Inc. (CDIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CDIO's current score at https://13fpro.ai/research/CDIO (free sign-up required for the full ranking).

Which hedge funds own the most CDIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CDIO include JANE STREET GROUP,, BOOTHBAY FUND MANAGEMENT,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CDIO as soon as new 13F filings post.

Where does 13F Pro source CDIO data?

All Cardio Diagnostics Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cardio Diagnostics Holdings, Inc. files with the SEC under CIK 1870144. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CDIO in?

Cardio Diagnostics Holdings, Inc. (CDIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CDIO research updated on 13F Pro?

CDIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cardio Diagnostics Holdings, Inc.(CDIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1870144 CDIO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CDIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cardio Diagnostics Holdings, Inc. (CDIO), a Healthcare sector company. CDIO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Cardio Diagnostics Holdings, Inc. reports quarterly revenue of $2.7K, net income of $-1.8M, free cash flow of $-1.6M. Top institutional holders of CDIO by reported 13-F value include JANE STREET GROUP,, BOOTHBAY FUND MANAGEMENT,, BlackRock,, based on the most recent SEC filings. CDIO trades on the Nasdaq exchange and files with the SEC under CIK 1870144. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardio Diagnostics Holdings, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$2.7K

Net Income

Q1 2026

$-1.8M

Free Cash Flow

Q1 2026

$-1.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-57.5% YoY

$14.8KFY 2025

FY20 —FY22 $950.00FY24 $34.9KFY25 $14.8K

Net Income

+22.5% YoY

$-6.5MFY 2025

FY20 —FY22 $-4.7MFY24 $-8.4MFY25 $-6.5M

Operating Income

+22.5% YoY

$-6.5MFY 2025

FY20 —FY22 $-4.5MFY24 $-8.4MFY25 $-6.5M

EPS (Diluted)

-1090.2% YoY

$-3.71FY 2025

FY20 —FY22 $-0.05FY24 $-0.31FY25 $-3.71

Total Assets

-26.8% YoY

$7.8MFY 2025

FY20 —FY22 $6.2MFY24 $10.6MFY25 $7.8M

Op. Cash Flow

-14.7% YoY

$-5.7MFY 2025

FY20 —FY22 $-5.1MFY24 $-5.0MFY25 $-5.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2020
Revenue	$14.8K -57.5%	$34.9K +3572.6%	$950.00	—
Net Income	$-6.5M +22.5%	$-8.4M -79.9%	$-4.7M	—
Operating Income	$-6.5M +22.5%	$-8.4M -83.9%	$-4.5M	—
EPS (Diluted)	$-3.71 -1090.2%	$-0.31 -519.7%	$-0.05	—
Total Assets	$7.8M -26.8%	$10.6M +69.9%	$6.2M	—
Operating Cash Flow	$-5.7M -14.7%	$-5.0M +1.9%	$-5.1M	—

AI Insight: CDIO Financial Trends

Pre-revenue biotech burning ~$1–2M quarterly with no clear path to commercialization; equity base volatile but modest leverage absent.

• Revenue remains at $0M across all eight quarters (Q2 2024–Q1 2026); no commercialization milestone achieved.

• Operating cash burn stable at $1–2M per quarter; Q4 2025 showed modest $1M burn, but Q1 2026 reverted to $2M.

• Equity declined from $11M (Q1 2025) to $9M (Q1 2026), reflecting cumulative net losses. No debt outstanding.

⚠ Equity base shrinking and now at $9M; at current burn rate, runway ~4–9 quarters without financing or cost cuts.

⚠ Operating losses consistently $1–2M per quarter with zero revenue signal; regulatory or clinical inflection needed urgently.

AI Insight: CDIO Ratio Trends

CDIO remains deeply unprofitable with deteriorating returns; ROE/ROA/ROIC all negative and worsening from Q1 2025 through Q3 2025 before modest stabilization in Q1 2026.

• ROE contracted from -57.5% in Q1 2025 to -84.1% in Q3 and Q4 2025, signaling accelerating shareholder value destruction mid-year.

• Q1 2026 ROE improved slightly to -80.3% from -84.1%, suggesting potential stabilization but returns remain severely negative.

⚠ ROA bottomed at -78.0% in Q3 2025; modest recovery to -74.8% in Q1 2026 warrants monitoring for sustainability.

⚠ Persistent negative profitability across all return metrics with no operational margin data reported limits visibility into underlying business recovery.

Get alerted when CDIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cardio Diagnostics Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CDIO

JANE STREET GROUP, LLC
$158.5K81,283 sh
BOOTHBAY FUND MANAGEMENT, LLC
$118.1K60,540 sh
BlackRock, Inc.
$67.7K34,708 sh
GEODE CAPITAL MANAGEMENT, LLC
$62.7K32,177 sh
VANGUARD CAPITAL MANAGEMENT LLC
$39.3K20,155 sh
RENAISSANCE TECHNOLOGIES LLC
$29.9K15,348 sh
Scientech Research LLC
$27.1K13,880 sh
UBS Group AG
$19.3K9,919 sh
VANGUARD FIDUCIARY TRUST CO
$7.7K3,969 sh
Tower Research Capital LLC (TRC)
$4.3K2,192 sh

Fund	Value	Shares
JANE STREET GROUP, LLC	$158.5K	81,283
BOOTHBAY FUND MANAGEMENT, LLC	$118.1K	60,540
BlackRock, Inc.	$67.7K	34,708
GEODE CAPITAL MANAGEMENT, LLC	$62.7K	32,177
VANGUARD CAPITAL MANAGEMENT LLC	$39.3K	20,155
RENAISSANCE TECHNOLOGIES LLC	$29.9K	15,348
Scientech Research LLC	$27.1K	13,880
UBS Group AG	$19.3K	9,919
VANGUARD FIDUCIARY TRUST CO	$7.7K	3,969
Tower Research Capital LLC (TRC)	$4.3K	2,192

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CDIO on your watchlist

Track score changes the day Cardio Diagnostics Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CDIO a good stock to buy?

13F Pro's AI-powered analysis of Cardio Diagnostics Holdings, Inc. (CDIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CDIO are available on the CDIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CDIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CDIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cardio Diagnostics Holdings, Inc.'s investment landscape.